Market research
ZLD.AU Zelira Therapeutics Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 11.7
- Dividend yield
- Not available
- Beta
- 0.61
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000ZLD1
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 11.7
- Dividend yield
- Not available
- Beta
- 0.61
About
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Research context
Zelira Therapeutics Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ZLD.AU discussion.
5 years, 6 months ago
Zelira Therapeutics Limited is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Zelira Therapeutics Limited's total revenue rose by 52.4% to $2M since the same quarter in the previous year.
Its net income has dropped by 39.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 49.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Zelira Therapeutics Limited gets an overall score of 2/5.